Age at HSCT (median) | 19-58 (28 years) |
|---|
Sex, F/M | 13/24 |
|---|
Diagnosis
|
AML | 13 |
B-ALL | 12 |
T-ALL | 2 |
CML | 2 |
SAA | 3 |
HL | 1 |
OMF | 1 |
MDS | 3 |
Treatment before HSCT
|
ANT | 29 |
cranial RT (24 Gy) | 14 |
mediastinal RT (24 Gy) | 2 |
Conditioning regimen
|
BUCY2 | 15 |
TBI+CY | 12 |
CY+ATG | 1 |
BCNU+VP-16+ARAC+MEL | 1 |
BU+FLU+CY | 3 |
FLU+CY+ATG | 2 |
BU+FLU+ATG | 1 |
FLAMSA | 2 |
- HSCT hematopoietic stem cell transplantation, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, SAA severe aplastic anemia, HL Hodgkin's lymphoma, OMF osteomyelofibrosis, MDS myelodysplastic syndrome, CY cyclophosphamide, BU busulphan, TBI total body irradiation, FLU fludarabine, ATG antithymocyte globulin, MEL melphalan, BCNU carmustine, VP-16 etoposide, ARAC cytosine arabinoside, FLAMSA fludarabine + cytosine arabinosid + TBI + CY + amsacrine was replaced by idarubicin, ANT anthracyclines
